NCT01040312 - An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors | Biotech Hunter

Enrollment

321

Participants

Timeline

Start Date

October 15, 2009

Primary Completion Date

September 29, 2014

Study Completion Date

September 2, 2015

Conditions

Small Cell Lung CancerNon-small Cell Lung CancerCervical CancerOvarian CancerGastric Cancer (Inoperable and Recurrent)

Interventions

DRUG

CPT-11

CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.

DRUG

Platinum analogues

Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.

Trial Locations (1)

359-8513

Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa